Welcome
F. Koinis
Lecture
Chairs: F. Koinis, A. Roussidis
Precision Medicine: The hope to improve better clinical outcomes in daily clinical oncology E.Papadopoulou
Chairs: G. Nasioulas, D.Hatzibougias
09.30-09.50 Τhe emerged importance of pathologist beyond the diagnostic workup
P. Foukas
09.50-10.10 How big polygenic panels do we need for tumor molecular profiling?
N. Pisimisis
10.10-10.30 RNA sequence: Could be emerged as a new tool for personalized treatment in cancer?
Ef. Kosmidis
10.30-10.50 HRD score: A new biomarker for PARP inhibitors
P. Konstantoulakis
10.50-11.10 Advancing cancer care with Comprehensive Genomic Profiling (CGP)
A. Grybos-Gajniak
sponsored by bioanalytica
11.10-11.20 Discussion
Coffee Break
Chairs: V. Georgoulias, P. Foukas
The importance of Liquid Biopsy as a tool for the understanding of the natural history and the metastatic process
E. Lianidou
Chairs: A. Markou, E. Galani
12.10-12.30 The phenotypic heterogeneity of Circulating Tumor Cells in breast cancer
G. Kallergi
12.30-12.50 The molecular heterogeneity of Circulating Tumor Cells in breast cancer
A. Strati
12.50-13.10 ESR1 mutation as a marker for hormone resistance treatment in breast cancer
D. Stergiopoulou
13.10-13.20 Discussion
Chairs: I. Kotteas, N. Spanakis
13.20-13.40 Clinical applications of Circulating Tumor Cells in breast cancer
A. Markou
13.40-14.00 Clinical applications of ctDNA in breast cancer
E. Karatrasoglou
14.00-14.10 Discussion
Light Lunch
Chairs: A. Strati, E. Kontopodis
15.00-15.20 The clinical relevance of CTC in prostate cancer
Α. Strati
15.20-15.40 The emerging importance of CTC in NSCLC
A. Ntzifa
15.40-16.00 the exosomes as a potential tool of tumor biomarkers
A. Xagara
16.00-16.10 Discussion
Chairs: G. Nasioulas, D. Ziogas
16.10-16.30 Newer biomarkers in NSCLC (EGFR exon 20 mut, KRAS mut, MET exon 14 mut)
D. Stefanou
16.30-16.50 Newer biomarkers in NSCLC (NTRK, RET, HER2 mut)
Th. Tegos
16.50-17.10 Germ line mutations of DNA Damage Repair (DDR) genes as therapeutic tumor biomarkers: Where do we stand?
O. Fiste
17.10-17.20 Discussion
Coffee break
Chairs: Ch. Kosmas, V. Georgoulias
17.50-18.10 Clinical applications of liquid biopsy in NSCLC
F. Papageorgiou
18.10-18.30 Monitoring of ctDNA for treatment efficacy in colorectal cancer patients
I. Samaras
18.30-18.50 Monitoring the Minimal Residual Disease using liquid Biopsy assays
A. Voutsina
18.50-19.10 The Signatera R platform for the detection of MRD
N. Tsoulos
19.10-19.20 Discussion
Chairs: P. Konstantoulakis, K. Tsigaridas
08.20-08.40 Emerging molecular subgroups in Colorectal cancers using NGS technology
M.Tzardi
08.40-09.00 Biomarkers in pancreatic and biliary tract carcinomas
D. Symeonidis
09.00-09.20 The NTRK fusions as a biomarker for personalized treatment
A. Kyriazoglou
Chairs: A. Karampeazis, E. Patsea
09.20-09.40 The prognostic and predictive value of TILs
I. Pateras
09.40-10.00 Is PD-L1 a real biomarker for treatment with ICIs?
I. Vamvakaris
10.00-10.20 Tumor Mutation Burden (TMB): When and How
G. Tsaousis
10.20-10.40 Intergrading MSI/MMR testing in the daily clinical practice
Α. Assi
Chairs: A. Kotsakis, F. Koinis
The emergence of Tissue-Agnostic treatment in clinical oncology
M. Rovithi
Closing Remarks